SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

11 Oct 2016 07:00

RNS Number : 1617M
Victrex PLC
11 October 2016
 
 

 

 

 

11 October 2016

Victrex plc: Full year and pre-close trading update

'Improved second half; good finish to 2016'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its full year and pre-close trading update for the financial year ended 30 September 2016, ahead of its preliminary results on 6 December 2016.

In line with expectations, Victrex delivered an improved performance in the second half and a good finish to 2016.

The core business was in growth, with Aerospace and Automotive performing well, and a more stable performance in Oil & Gas during the second half. Sales volumes for the large Consumer Electronics business were delivered on plan during Q4, with overall second half volumes more than double those in the first half. Q4, overall, saw a good performance with Group revenue up 8% to £73.7m (Q4 2015: £68.0m) and Q4 Group sales volume up 9% to 1,216 tonnes (Q4 2015: 1,119 tonnes).

Despite a positive finish to 2016, full year Group revenue declined by 4% to £252.3m (FY2015: £263.5m), reflecting the year on year fall in Consumer Electronics volumes, which were more than 30% down. Full year Group sales volume was down 6% at 3,952 tonnes (FY 2015: 4,217 tonnes).

Medical revenue (Invibio) for the full year of £50.8m (FY 2015: £50.5m) reflects a stable Spine market in the US. Growth outside of the US, in emerging markets, remains positive.

Our mega-programmes continue to make progress, with the Magma Oil & Gas project delivering first meaningful revenues of over £1m in FY16. Incremental investment opportunities aligned to our mega-programmes are also being progressed, which would further support delivery of the Group's downstream strategy and growth pipeline.

 

Outlook

 

As we start our new financial year, our core business remains robust. However, we remain mindful, as previously communicated, that our early planning assumption suggests Consumer Electronics volumes will be significantly lower in 2017, compared to 2016. This would also impact our operating leverage.

 

Whilst we will continue to invest in our 'front end' commercial, marketing and technical functions, to help drive adoption of our mega-programmes, we will also further enhance our ongoing focus on cost efficiency opportunities over the coming year.

 

With a differentiated strategy, a strong pipeline and a highly cash generative business model, Victrex remains in a good position to drive shareholder value for the medium to longer term.

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Teneo Blue Rubicon:

Charles Armitstead +44 (0) 207 260 2700

 

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the Automotive, Aerospace, Energy, Electronics and Medical markets. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we deliver leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGGGBUUUPQGQU
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.